



## **I. DISCOVERY CONTROL PLAN**

1.1 Plaintiff, the State of Texas, designates this case as a Level 3 case requiring a discovery control plan tailored to the circumstances of this specific suit. An agreed scheduling order is in place.

## **II. DEFENDANTS**

The Defendants complained of and sued in this action are:

2.1 Roxane Laboratories, Inc. ("Roxane") is a corporation organized under the laws of Delaware with its principal offices in Columbus, Ohio, and is a subsidiary of Boehringer Ingelheim Corporation. At all times material to this civil action, Roxane has transacted business in the State of Texas by, including but not limited to, selling and distributing to purchasers in the State of Texas pharmaceutical products that are the subject of this action, but does not maintain a regular place of business in this state or a designated agent for service of process.

2.2 Boehringer Ingelheim Pharmaceuticals, Inc. ("BIPI") is a corporation organized under the laws of Delaware with its principal offices in Ridgefield, Connecticut, and is a subsidiary of Boehringer Ingelheim Corporation. BIPI does not maintain a regular place of business in this state, but may be served with process by service upon its registered agent, CT Corporation System, 350 North St. Paul Street, Dallas, Texas 75201. At all times material to this civil action, BIPI has transacted business in the State of Texas by providing active support, assistance and resources to Defendants Roxane and Ben Venue which allowed those companies to engage in the reporting of false and fraudulent information to State and Federal Medicaid officials relating to the drugs listed in paragraph 4.3 and in Exhibit A. This defendant facilitated, directed and participated in the marketing, production, sale and distribution of the drugs listed in paragraph 4.3 and in Exhibit A.

2.3 Ben Venue Laboratories, Inc. ("Ben Venue") is a corporation organized under the laws of Delaware with its principal offices in Bedford, Ohio, and is a subsidiary of Boehringer

Ingelheim Corporation. Ben Venue does not maintain a regular place of business in this state nor does it maintain a registered agent for service of process. At all times material to this civil action, Ben Venue has transacted business in the State of Texas by, including but not limited to, selling, marketing, and/or distributing to purchasers in the State of Texas pharmaceutical products that are the subject of this action as listed in paragraph 4.3 and in Exhibit A. The management, supervision, control, reporting and financial exchanges by and between Ben Venue, BIPI, and Roxane are inextricably intertwined and justify the exercise of personal jurisdiction over this Defendant.

2.4 Boehringer Ingelheim Corporation ("Boehringer") is a corporation organized under the laws of Nevada with its principal offices in Ridgefield, Connecticut, and is the parent company of Roxane, BIPI, and Ben Venue. Boehringer does not maintain a regular place of business in this state nor does it maintain a registered agent for service of process. At all times material to this civil action, Boehringer and its subsidiaries have transacted business in the State of Texas by, including but not limited to, selling and distributing to purchasers in the State of Texas pharmaceutical products that are the subject of this action as listed in paragraph 4.3 and in Exhibit A. The management, supervision, control, reporting and financial exchanges by and between Boehringer and its subsidiaries, BIPI, Roxane and Ben Venue are inextricably intertwined and justify the exercise of personal jurisdiction over this Defendant.

### **III. RESPONDEAT SUPERIOR AND VICARIOUS LIABILITY**

3.1 When the several Defendants herein are collectively referred to as the "Defendants", the allegations contained in that sentence and paragraph are alleged jointly and severally against each separate Defendant in that these Defendants are corporations whose operations are inextricably intertwined and who were acting in concert together to foster, facilitate and promote the actionable fraud alleged herein. It is alleged that employees and officers

of all the Defendant Corporations acted in harmony and concert to commit the illegal acts specified in paragraphs 7 and 8.

3.2 The Defendants are related entities sharing common elements of management, finances, control, supervision, and reporting and thus are mutually, jointly, and severally liable under legal theories of respondeat superior, and the past, present and continuing relations and dealings by and between these related entities are so inextricably intertwined that for purposes of this suit, some or all of them should be considered as a single entity at law and equity.

#### **IV. PRELIMINARY STATEMENT AND NATURE OF THE ACTION**

4.1 This is an action under the common law and the Texas Medicaid Fraud Prevention Act (hereinafter sometimes referred to as "TMFPA," or "the Act") for restitution, damages, pre-judgment interest, civil penalties of not less than \$1,000.00 or more than \$10,000.00 for each unlawful act, two (2) times the value of the payments, and recovery of costs, attorneys' fees, and expenses of the Attorney General of the State of Texas and Ven-A-Care against Defendants, as well as any and all other monetary amounts as may be allowed at law or in equity under Section 36.052.

4.2 The Defendants knowingly or intentionally made false representations of prices and costs for certain of their drugs directly or indirectly to the Texas Medicaid Program. The drugs in question are listed in paragraph 4.3 and in Exhibit A. The Defendants knew that the Texas Medicaid Program intended, and was required, to base its payments of the drug reimbursement claims submitted by physicians, pharmacies, and other providers on estimates of acquisition costs incurred by such providers for the drugs, and that the Texas Medicaid Program

would use the price and cost representations of the Defendants in estimating providers' acquisition costs. As a result of misrepresentations of drug prices and costs by Defendants, Texas Medicaid estimated the provider acquisition costs for the drugs in question to be excessive. Thus, the Texas Medicaid Program was defrauded by the Defendants into paying reimbursement for the Defendants' drugs in excessive amounts.

4.3 In the course of the Plaintiffs' investigation of the facts of this case, the following drugs have been identified as ones for which the Defendants reported false and misleading prices to, or concealed the true prices from the State: Acetaminophen, Acetylcysteine, Albuterol, Atrovent, Azathioprine, Butorphanol, Calcium Carbonate, Calcitrol, Chlorpromazine, Codeine Sulfate, Cromolyn, Cyclophosphamide, Dexamethasone, Diclofenac Sodium, Digoxin, Diphenoxylate/Atropine Etoposide, Fluphenazine, Furosemide, Haloperidol, Hydromorphone, Hydroxyurea, Ipecac Syrup, Ipratropium Bromide, Isoetharine Solution, Lactulose, Leucovorin Calcium, Lidocaine, Lithium, Lorazepam, Marinol, Megestrol, Meperidine, Methadone, Methotrexate, Metoclopramide, Mexiletine HCL, Mirtazapine, Morphine Sulphate, Naproxen, Nefazodone, Oramorph, Oxycodone, Prednisone, Propantheline, Propranolol, Pseudoephedrine, Ranitidine, Roxanol, Roxicet, Roxicodone, Roxiprin, Sodium Chloride, Sodium Polystyrene Sulfonate, Theophylline, Tamoxifen, Torecan, and Triazolam.

4.4 A list of the specific National Drug Code (NDC) numbers for these drugs is attached as Exhibit "A" and incorporated by reference herein. The drugs listed on Exhibit "A" shall be referred to hereafter as the "Identified Drugs." During the discovery phase of this case, Plaintiffs may discover evidence of additional drugs for which Defendants misrepresented prices

to the State. In such an event, those drugs will be added to Exhibit "A" by amendment of this petition, as is being done in this amendment.

4.5 The Defendants marketed their drugs to wholesalers, distributors, group purchasing organizations, pharmacies, home health care companies, and other customers, through financial inducements, including but not limited to: false price markups, the difference between acquisition cost and reimbursement (the "Spread"), discounts, rebates, chargebacks, free goods, and other financial incentives. The Defendants marketed their products directly through sales visits and presentations, telemarketing, and other forms of contact with their customers, as well as indirectly through various pharmacy inventory software designed to identify those products with the largest spread.

4.6 In September 1996, Defendants BIPI and Roxane, by and through its multisource marketing manager, Judy Waterer, orchestrated a marketing scheme involving two of the Identified Drugs in this case, Atrovent and Ipratropium Bromide, which resulted in price misrepresentations to the Texas Medicaid Program by the Defendants. Anticipating the imminent introduction by Dey Labs, Inc., of the first generic competitor for Roxane's Ipratropium Bromide, Roxane enticed preferred home health care customers to enter into contracts to purchase large quantities of Ipratropium Bromide by offering those customers Defendant BIPI's Atrovent as a substitute for Roxane's Ipratropium Bromide at very low generic prices. The purpose of this scheme was to capture as much of the rapidly expanding home health care market as possible before Dey Labs launched its competitive generic Ipratropium Bromide product. The home health care market was extremely important to the success of

Roxane's Ipratropium Bromide, and that market was historically dominated by Dey Labs. Roxane knew that offering BIPI's Atrovent as a substitute for Roxane's Ipratropium Bromide at very low generic prices without disclosing that fact to government reimbursement programs, such as the Texas Medicaid Program, would ensure purchasers excessive reimbursement from those programs and thus would provide a tremendous financial incentive for home health care customers to purchase Ipratropium Bromide through Roxane in the short term. After all, BIPI's Atrovent and Roxane's generic Ipratropium Bromide are the identical pharmaceutical product, manufactured under the same New Drug Application in the same production facilities, with the only differences being the packaging and the pricing. Roxane also appreciated that this substitution offering would expand and strengthen its long-term contractual relationships with those home health customers.

4.7 The relationship of BIPI, Roxane, and their common parent, BIC, enabled them to implement this scheme. Without the interrelationship of those three corporate defendants, this particular scheme would not have been possible.

4.8 Home health care providers participating in the Texas Medicaid program were among those who purchased BIPI's Atrovent at low generic prices. The Defendants concealed from the Texas Medicaid program the fact that Atrovent was being sold at these heavily discounted prices to the home health care market, when in fact, it was being sold at these low generic prices in extremely large quantities throughout Texas. This concealment of the low generic price at which Atrovent was being sold to Texas home health care providers caused the Texas Medicaid program to make excessive reimbursement payments to those providers.

## **V. JURISDICTION & VENUE**

5.1 Jurisdiction over the subject matter is founded in part upon the TMFPA, which prohibits, and provides exclusive remedies to redress, the conduct of the Defendants and which provides for this action to be brought by the State of Texas and by Private Person Plaintiff, Ven-A-Care.

5.2 Venue is proper in Travis County pursuant to TEX. HUM. RES. CODE § 36.052(d) in that many of the unlawful acts committed by the Defendants were committed in Travis County including the making of false statements and misrepresentations of material fact to the State of Texas, its departments, agencies, instrumentalities, contractors, and to the Texas Medicaid Program.

5.3 Additionally, venue is proper against these Defendants in Travis County as all or a substantial portion of the events giving rise to the instant claims occurred in Travis County. TEX. CIV. PRAC. & REM. CODE §§ 15.001, 15.002 (Vernon 2001).

## **VI. BACKGROUND: HOW PHARMACEUTICAL CLAIMS ARE PAID UNDER THE TEXAS MEDICAID PROGRAM**

6.1 The Texas Medicaid Program reimburses eligible providers, including pharmacies, for the approved pharmaceuticals they provide to Medicaid recipients. The Texas Vendor Drug Program (TVDP) of the Texas Health and Human Services Commission ("THHSC")<sup>1</sup> administers this program. Providers can obtain reimbursement through the TVDP only for

---

<sup>1</sup> The Vendor Drug Program was transferred from the Texas Department of Health to the Texas Health and Human Services Commission.

products listed on the Texas Drug Code Index. 25 TEX. ADMIN. CODE § 35.201. To have its particular pharmaceutical products listed on the index, a drug company or manufacturer must file and have approved an application for its products with the Texas Department of Health. 25 TEX. ADMIN. CODE § 35.801. Section 2 of the application requires the manufacturer to report, for each drug submitted, the suggested wholesale price to pharmacies, the price at which the drug is sold to wholesalers and/or distributors, the direct price to pharmacies, the price to chain warehouses and the price at which the drug is sold to any other special purchasing groups. Additionally, the form contains a separate question in section 4 inquiring whether the drug company sells the drug to wholesalers and/or distributors. The application requires that a manufacturer certify that the information it has provided is correct and that it will provide correct information regarding subsequent changes in pricing of the product within 15 days of such changes occurring. Further, in approving the application, THHSC expressly requires that supplemental updated price information be timely provided.

6.2 THHSC bases its reimbursement schedule on the prices reported by the manufacturer on the application, and on subsequent price changes supplied by the manufacturer. Reimbursement to a pharmaceutical provider (i.e., a pharmacy or physician) is based on HHSC's best estimate of acquisition cost, referred to as ("EAC"). 1 TEX. ADMIN. CODE § 355.8541 (1).

6.3 When a manufacturer reports false pricing information to or conceals true pricing information from TVDP, the agency's calculation of estimated acquisition cost ("EAC") is inflated and thus the reimbursement schedule is also inflated. These circumstances result in drug reimbursement overpayments to drug providers by the State.

## VII. ACTIONABLE CONDUCT OF DEFENDANTS

7.1 The Defendants knew that by reporting false prices and costs for the Identified Drugs and concealing and failing to report truthful pricing information they would cause the Texas Medicaid Program to overestimate acquisition costs for their drugs and thus to pay excessive reimbursement to Medicaid providers for their drugs. Notwithstanding this knowledge, the Defendants reported false or misleading price and cost information and concealed and failed to disclose price reductions and truthful pricing information about the Identified Drugs to accomplish that result; i.e., to cause the Texas Medicaid program to pay excessive reimbursements for the Identified Drugs. The Defendants' actions created "spreads" between the acquisition costs of the Identified Drugs and the amounts reimbursed for those drugs by Medicaid. Defendants believed and intended that these "spreads" would financially benefit the Defendants' Texas Medicaid provider customers.

7.2 The Defendants were fully capable of making truthful representations about prices and costs of the Identified Drugs. To the Plaintiffs' knowledge, they did so when it was economically beneficial to them, such as when they reported pricing information for Medicaid reimbursement purposes for certain of their drugs that did not face generic or other competition.

7.3 Notwithstanding the Defendants' knowledge that they were required to provide truthful price information vital to Texas Medicaid's ability to estimate provider acquisition costs, the Defendants knowingly or intentionally reported misleading price information about the Identified Drugs and concealed or failed to disclose truthful price information.

7.4 In one or more of the following ways, the Defendants acted knowingly or intentionally in making false statements and misrepresentations of material fact to the Texas Medicaid program, and in concealing from or failing to disclose the truth to the Texas Medicaid program:

- A. Reporting false prices and concealing true prices on initial applications to have the Identified Drugs covered by Texas Medicaid;
- B. Concealing or otherwise failing to disclose decreases in the prices or costs of the Identified Drugs;
- C. Concealing or otherwise failing to disclose transactions, practices, and terms of sale, such as discounts, rebates, off-invoice pricing, free goods, cash payments, chargebacks, and other financial incentives and inducements, that decrease the cost, and thereby the price, of the Identified Drugs to purchasers;
- D. Reporting that the price or cost of an Identified Drug was increasing when it in fact was increasing in a lesser proportion, or remained the same, or was decreasing;
- E. Reporting that the price or cost of an Identified Drug was the same when in fact it was falling; and
- F. Reporting that an Identified Drug was not sold to a specific sector or segment of the market (also known as a "class of trade") when in fact it was, regularly and in significant quantities, and concealing or failing to disclose such facts.

**VIII. THE DEFENDANTS' ACTIONS CONSTITUTE "UNLAWFUL ACTS"**  
**AND VIOLATE THE TEXAS MEDICAID FRAUD PREVENTION ACT**

8.1 Defendants have repeatedly and continuously violated the TMFPA. The Act specifies 10 separate acts that are declared to be unlawful. Each of the Defendants committed at least three of those unlawful acts on numerous occasions:

(a) The Act prohibits a person from knowingly or intentionally making or causing to be made a false statement or misrepresentation of material fact on an application for a contract, benefit, or payment under the Medicaid Program; or that is intended to be used to determine a person's eligibility for a payment under the Medicaid Program. TEX. HUM. RES. CODE § 36.002(1).

(b) The Act prohibits a person from knowingly or intentionally concealing or failing to disclose an event that permits a person to receive a benefit or payment that is not authorized, or that permits a person to receive a benefit or payment that is greater than the benefit or payment that is authorized. TEX. HUM. RES. CODE §36.002(2).

(c) The Act prohibits a person from knowingly or intentionally making or causing to be made a false statement or misrepresentation of fact concerning information required to be provided by a federal or state law, rule, regulation or provider agreement pertaining to the Medicaid Program. TEX. HUM. RES. CODE § 36.002(4).

8.2 In the TMFPA, The Texas Legislature has specified acts and omissions that are illegal. Those acts and omissions give rise to civil and criminal liability and penalties that can be imposed against drug manufacturers such as the Defendants, who voluntarily chose to place their

respective products into the Texas Medicaid Vendor Drug Program and thus are subject to and bound by the laws, rules, regulations, and agreements pertinent thereto. The TMFPA provides no statutory defenses and contains no references to common law defenses or allowances for mitigation and none of these are allowed.

**IX. THE DEFENDANTS' SELECTIVE REPORTING OF FALSE PRICE INFORMATION REVEALS THAT THEY ACTED KNOWINGLY**

9.1 The Defendants were motivated to misrepresent price information regarding the Identified Drugs because they believed these misrepresentations would make these drugs more attractive to providers. For this reason, the Defendants created enhanced "spreads" between their misrepresentative reported prices and their generally and currently available market prices to providers. In contrast, when a Defendant stood to gain no marketing advantage for other drugs by creating an inflated reimbursement, it typically reported prices that reflected the prices generally and currently available to pharmacy providers. This contrasting behavior reveals that the Defendants know the difference between misleading and non-misleading pricing data; that non-misleading pricing data was available to them; that they chose whether to report misleading or non-misleading pricing data as to particular drugs; that they had a motive to report misleading pricing data on the Identified Drugs; and that their reporting of false information was no accident, but was planned. Therefore, evidence that a Defendant routinely reported non-misleading prices for certain other drugs and misleading prices for the Identified Drugs is relevant and admissible:

1. Under T.R.E. 401, as tending to prove a fact of consequence to the determination of the action, i.e., that the Defendants acted knowingly, and not by accident or

mistake, in reporting false and misleading pricing information on the Identified Drugs;

2. Under T.R.E. 404 (b) as proof of motive, opportunity, intent, plan, knowledge and absence of mistake or accident;
3. Under T.R.E. 406 as proof of routine practice to consistently act illegally when profit resulted, yet legally when the profit motive was absent or less compelling, and to show that a defendant was able to comply with the law, did know how to report prices that were not misleading, and did so when the motive to act illegally was lessened or missing; and
4. Under T.M.F.P.A. § 36.052 (b)(1) through (5) for assessment of a civil penalty.

#### **X. DAMAGES**

10.1 Pursuant to the terms of the Medicaid Fraud Prevention Act, each Defendant is liable to the State of Texas for the value of any payment . . . provided under the Medicaid program, directly or indirectly, as a result of the unlawful act. TEX. HUM. RES. CODE § 36.052(1). If Defendants contend that their actions were performed separate and apart, as distinct and different corporate entities, therefore each separate corporation is severally and individually liable for actual damages as defined by statute (T.M.F.P.A. § 36) as well as civil penalties as a result of their individual unlawful act(s). Additionally, each Defendant is liable for interest on the value of the payment, civil penalties ranging from \$1,000 to \$10,000 for each unlawful act, two

times the value of the payment, and all fees, expenses, and costs reasonably incurred. *Id.* at (2), (3), & (4) *and* § 36.007.

10.2 Plaintiff and Relator invoke in the broadest sense all relief possible at law or in equity under § 36.052, whether specified in this pleading or not. Plaintiffs will seek an amount as civil penalties which will be justified and appropriate under the facts relevant to this issue and under the laws as determined by the Court.

10.3 Discovery in this case is ongoing. Plaintiffs have diligently sought for months to discover financial data and pricing information from Defendants. Such information and data is exclusively in the possession and subject to the control of defendants. Defendants obviously and without doubt possess and maintain data reflecting and revealing their bona fide and genuine prices that resulted in net cash flow to Defendants for the relevant drugs subject of this case. However, Defendants have fiercely resisted producing and revealing this bona-fide pricing information. Plaintiffs have moved to compel the production of the bona-fide pricing data and for sanctions for the failure to have done that without protest. Within a reasonable period of time after bona-fide pricing information is produced (To the Court only: Just as with prior defendants Warrick and Dey.), Plaintiffs will be in a position to plead a maximum amount of monetary damages resulting from the fraud and violations of the TMFPA by Defendants. Until such time as the Defendants meet their obligations to produce such data and information Plaintiffs continue to allege that maximum damages are in an amount in excess of the minimum limits of this Honorable Court.

10.4 The TMFPA is a statute of absolute strict liability. There are no defenses available for any violation of its provisions and in particular any violation of any part of § 36.002 of the TMFPA. Likewise, according to the Texas Supreme Court, as a matter of law the defenses of estoppel, laches, and limitations are not available against the State of Texas, as a Sovereign. *State v. Durham*, 860 S.W.2d 63, 67 (Tex. 1993).

10.5 In order for the trier of fact to be apprised of relevant and probative information upon which to assess a finding of an appropriate civil penalty, the jury will need to receive and hear evidence relating to TMFPA § 36.052 (b) (1)-(4) inclusive. Specifically the trier of fact must receive evidence on the following topics:

- (1) previous and other violations of the law;
- (2) the seriousness of the unlawful act, "...including the nature, circumstances, extent, and gravity of the unlawful act;"
- (3) whether the health and safety of the public was threatened; and
- (4) whether the person acted in bad faith when engaged in the conduct that formed the basis of the unlawful act.

#### **XI. JURY DEMAND**

11.1 The State respectfully requests a trial by jury pursuant to Tex. R. Civ. P. 216.

#### **XII. PRAYER**

12.1 The State asks that it recover from the Defendants restitution of overpayments, statutory additional double damages, pre-judgment interest, attorneys fees, costs, and expenses

and civil penalties as provided in TEX. HUM. RES. CODE ANN., Chapter 36 Plaintiff and Relator invoke in the broadest sense all relief possible at law or equity under Texas Human Resources Code, Chapter 36 without qualification or limitation. The State asks that upon trial of this case that judgment be entered in favor of the State and against the Defendants in the amounts set forth herein. The Relator further asks that it be awarded its costs and expenses; a reasonable attorney fee; and the maximum Relator's share provided for under the TMFPA. The State prays for such other and further relief to which it may show itself entitled either at law or in equity.

Respectfully submitted,

GREG ABBOTT  
Attorney General of Texas

BARRY McBEE  
First Assistant Attorney General

EDWARD D. BURBACH  
Deputy Attorney General for Litigation


MARK TOBEY  
Chief, Antitrust & Civil Medicaid Fraud Division

*Patrick J. O'Connell by Permission*  
*JVE*  
PATRICK J. O'CONNELL  
Assistant Attorney General  
Chief, Civil Medicaid Fraud Section  
State Bar No. 15179900

CYNTHIA O'KEEFFE  
Assistant Attorney General  
State Bar No. 08505000  
P. O. Box 12548  
Austin, Texas 78711-2548  
(512) 936-1304  
(512) 499-0712 [Fax]

JOSEPH V. CRAWFORD  
Wright & Greenhill, P.C.  
State Bar No. 05030600  
221 West 6<sup>th</sup> Street, Suite 1800  
Austin, Texas 78701-3495  
(512) 476-4600  
FAX: (512) 476-5382

ATTORNEYS FOR THE STATE OF TEXAS

  
JOHN E. CLARK

State Bar No: 04287000

Goode Casseb Jones

Riklin Choate & Watson

2122 North Main Avenue

P.O. Box 120480

San Antonio, Texas 78212-9680

Telephone: 210-733-6030

Facsimile: 210-733-0330

JAMES J. BREEN

Florida Bar No. 297178

The Breen Law Firm, P.A.

P.O. Box 297470

Pembroke Pines, Florida 33029-7470

Phone: (954) 499-1171

Facsimile: (954) 499-1173

C. JARRETT ANDERSON

State Bar No. 00796124

Anderson LLC

1300 Guadalupe, Suite 103

Austin, Texas 78701

Phone: (512) 469-9191

Facsimile: (512) 478-1023


SUSAN SCHNEIDER THOMAS  
Pennsylvania Bar No. 32799  
GARY AZORSKY  
Pennsylvania Bar No. 38924  
Berger & Montague, P.C.  
1622 Locust Street  
Philadelphia, PA 19103  
Telephone: (215) 875-3000  
Fax: (215) 875-4636  
ATTORNEYS FOR RELATOR,  
VEN-A-CARE OF THE FLORIDA KEYS, INC.

**CERTIFICATE OF SERVICE**

I hereby certify that a true and correct copy of the foregoing **Fourth Amended Original Petition** was sent via hand delivery on this the **14** day of April, 2005, to the following:

Mr. Steve McConnico  
Scott, Douglas & McConnico, LLP  
600 Congress Avenue, 15<sup>th</sup> Floor  
Austin, Texas 78701-2589

COUNSEL FOR ROXANE LABORATORIES, INC.,  
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.,  
BEN VENUE LABORATORIES, INC., and BOEHRINGER  
INGELHEIM CORPORATION

  
JOSEPH V. CRAWFORD

**EXHIBIT A  
IDENTIFIED DRUGS**

NDC	Description
00054002025	LITHIUM ER 450MG TABLET
00054004544	IPRATROPIUM 0.03% SPRAY
00054004641	IPRATROPIUM 0.06% SPRAY
00054170125	TORECAN 5MG/ML AMPUL
00054224725	HYDROXYUREA 500MG CAPSULE
00054252725	LITHIUM CARBONATE 300MG CAP
00054252731	LITHIUM CARBONATE 300MG CAP
00054253125	LITHIUM CARBONATE 600MG CAP
00054260111	MARINOL 2.5MG CAPSULE
00054260211	MARINOL 5MG CAPSULE
00054260311	MARINOL 10MG CAPSULE
00054261625	MEXILETINE HCL 150MG CAPSULE
00054261725	MEXILETINE HCL 200MG CAPSULE
00054261825	MEXILETINE HCL 250MG CAPSULE
00054279525	OXYCODONE W/APAP 5/500 CAP
00054302502	ACETYLCYSTEINE 10% VIAL
00054302602	ACETYLCYSTEINE 20% VIAL
00054302702	ACETYLCYSTEINE 10% VIAL
00054302802	ACETYLCYSTEINE 20% VIAL
00054309036	BUTORPHANOL 10MG/ML SPRAY
00054311763	CALCIUM CARB 500MG/5ML SUSP
00054312041	CALCITRIOL 1MCG/ML SOLUTION
00054314658	CHLORPROMAZINE 100MG/ML CON
00054317644	DEXAMETHASONE 0.5MG/0.5ML DROP
00054319246	DIGOXIN 0.05MG/ML ELIXIR
00054319446	DIPHENOXYLATE/ATROPINE LIQ
00054329863	FUROSEMIDE 40MG/5ML SOLN
00054429725	FUROSEMIDE 20MG TABLET
00054429925	FUROSEMIDE 40MG TABLET
00054430125	FUROSEMIDE 80MG TABLET
00054430129	FUROSEMIDE 80MG TABLET
00054329446	FUROSEMIDE 10MG/ML SOLN
00054329450	FUROSEMIDE 10MG/ML SOLN
00054429731	FUROSEMIDE 20MG TABLET
00054429931	FUROSEMIDE 40 MG TABLET
00054335050	HALOPERIDOL LAC 2MG/ML CONC

NDC	Description
00054340840	ISOETHARINE 1% SOLUTION
00054340844	ISOETHARINE 1% SOLUTION
00054348658	LACTULOSE 10GM/15ML SOLUTION
00054348668	LACTULOSE 10GM/15ML SYRUP
00054350049	LIDOCAINE 2% VISCOUS SOLN
00054350547	LIDOCAINE HCL 4% SOLUTION
00054352763	LITHIUM CIT 8MEQ/5ML SYRUP
00054353244	LORAZEPAM 2MG/ML ORAL CONC.
00054354258	MEGESTROL ACET 40MG/ML SUSP
00054354563	MEPERIDINE 50MG/5ML SYRUP
00054355344	METHADONE INTENSOL 10MG/ML
00054355563	METHADONE 5MG/5ML SOLUTION
00054355663	METHADONE 10MG/5ML SOLUTION
00054356363	METOCLOPRAMIDE 5MG/5ML SYR
00054356444	METOCLOPRAMIDE 10MG/ML SOLN
00054363063	NAPROXEN 125MG/5ML SUSPEN
00054368344	ROXICODONE INTENSOL 20MG/ML
00054372144	PREDNISONE 5MG/ML SOLUTION
00054372250	PREDNISONE 5MG/5ML SOLUTION
00054372763	PROPRANOLOL 20MG/5ML SOLN
00054373063	PROPRANOLOL 40MG/5ML SOLN
00054375144	ROXANOL 20MG/ML SOLUTION
00054375150	ROXANOL 20MG/ML SOLUTION
00054375158	ROXANOL 100MG/5ML SOLUTION
00054377444	ROXANOL-T 20MG/ML SOLUTION
00054377450	ROXANOL-T 20MG/ML SOLUTION
00054378563	MORPHINE SULF 10MG/5ML SOLN
00054378663	MORPHINE SULF 20MG/5ML SOLN
00054380563	SPS 15GM/60ML SUSPENSION
00054384163	THEOPHYLLINE 80MG/15ML SOLN
00054384168	THEOPHYLLINE 80MG/15ML SOLN
00054401431	ACETAMINOPHEN 325MG TABLET
00054408425	AZATHIOPRINE 50MG TABLET
00054412025	CALCIUM CARBONATE 1.25GM TB
00054412925	CYCLOPHOSPHAMIDE 25MG TAB
00054413025	CYCLOPHOSPHAMIDE 50MG TAB
00054415625	CODEINE SULFATE 30MG TABLET
00054415725	CODEINE SULFATE 60MG TABLET
00054417925	DEXAMETHASONE 0.5MG TABLET
00054417931	DEXAMETHASONE 0.5MG TABLET

NDC	Description
00054418025	DEXAMETHASONE 0.75MG TABLET
00054418125	DEXAMETHASONE 1MG TABLET
00054418225	DEXAMETHASONE 1.5MG TABLET
00054418325	DEXAMETHASONE 2MG TABLET
00054418425	DEXAMETHASONE 4MG TABLET
00054418625	DEXAMETHASONE 6MG TABLET
00054422121	DICLOFENAC SODIUM 50MG SA TAB
00054422125	DICLOFENAC SODIUM 50MG SA TAB
00054422131	DICLOFENAC SODIUM 50MG SA TAB
00054422221	DICLOFENAC SODIUM 75MG SA TAB
00054422225	DICLOFENAC SODIUM 75MG SA TAB
00054422231	DICLOFENAC SODIUM 75MG SA TAB
00054422321	DICLOFENAC SODIUM 25MG SA TAB
00054422325	DICLOFENAC SODIUM 25MG SA TAB
00054434225	HALOPERIDOL 0.5MG TABLET
00054434325	HALOPERIDOL 1MG TABLET
00054434331	HALOPERIDOL 1MG TABLET
00054434425	HALOPERIDOL 2MG TABLET
00054434431	HALOPERIDOL 2MG TABLET
00054434525	HALOPERIDOL 5MG TABLET
00054434531	HALOPERIDOL 5MG TABLET
00054434625	HALOPERIDOL 10MG TABLET
00054434631	HALOPERIDOL 10MG TABLET
00054434725	HALOPERIDOL 20MG TABLET
00054437025	HYDROMORPHONE HCL 8MG TAB
00054439225	HYDROMORPHONE 2MG TABLET
00054439425	HYDROMORPHONE 4MG TABLET
00054449613	LEUCOVORIN CALCIUM 5MG TAB
00054449625	LEUCOVORIN CALCIUM 5MG TAB
00054449705	LEUCOVORIN CALCIUM 10MG TAB
00054449710	LEUCOVORIN CALCIUM 10MG TAB
00054449805	LEUCOVORIN CALCIUM 15MG TAB
00054449810	LEUCOVORIN CALCIUM 15MG TAB
00054449911	LEUCOVORIN CALCIUM 25MG TAB
00054452725	LITHIUM CARBONATE 300MG TAB

NDC	Description
00054452731	LITHIUM CARBONATE 300MG TAB
00054453825	METHADONE HCL 40MG DISKET
00054455015	METHOTREXATE 2.5MG TABLET
00054455025	METHOTREXATE 2.5MG TABLET
00054457125	METHADONE HCL 10MG TABLET
00054458225	MORPHINE SULFATE 15MG TAB
00054458325	MORPHINE SULFATE 30MG TAB
00054459625	MEPERIDINE 100MG TABLET
00054460325	MEGESTROL 20MG TABLET
00054460425	MEGESTROL 40MG TABLET
00054465025	ROXICET 5/325 TABLET
00054465029	ROXICET 5/325 TABLET
00054465325	ROXIPRIN 4.88/325 TABLET
00054465331	ROXIPRIN 4.88/325 TABLET
00054465725	ROXICODONE 5MG TABLET
00054465825	ROXICODONE 15MG TABLET
00054466525	ROXICODONE 30MG TABLET
00054467321	NEFAZODONE HCL 150MG TABLET
00054467713	MIRTAZAPINE 30MG TABLET
00054467813	MIRTAZAPINE 45MG TABLET
00054472125	PROPANTHELINE 15MG TABLET
00054472131	PROPANTHELINE 15MG TABLET
00054474125	PREDNISONE 1MG TABLET
00054474131	PREDNISONE 1MG TABLET
00054474325	PSEUDOEPHEDRINE 30MG TABLET
00054478425	ROXICET 5/500 CAPLET
00054479025	ORAMORPH SR 15MG TABLET SA
00054479225	ORAMORPH SR 60MG TABLET SA
00054479325	ORAMORPH SR 100MG TABLET SA
00054480519	ORAMORPH SR 30MG TABLET SA
00054480525	ORAMORPH SR 30MG TABLET SA
00054480527	ORAMORPH SR 30MG TABLET SA
00054483121	TAMOXIFEN 10MG TABLET
00054485321	RANITIDINE 150MG TABLET
00054485325	RANITIDINE 150MG TABLET
00054485329	RANITIDINE 150MG TABLET
00054485425	RANITIDINE 300MG TABLET
00054485806	TRIAZOLAM 0.125MG TABLET
00054485829	TRIAZOLAM 0.125MG TABLET
00054485906	TRIAZOLAM 0.25MG TABLET
00054485929	TRIAZOLAM 0.25MG TABLET
00054806311	ALBUTEROL .83MG/ML SOLUTION

NDC	Description
00054806313	ALBUTEROL .83MG/ML SOLUTION
00054806321	ALBUTEROL .83MG/ML SOLUTION
00054816721	CROMOLYN NEBULIZER SOLUTION
00054816723	CROMOLYN NEBULIZER SOLUTION
00054840211	IPRATROPIUM BR 0.02% SOLN
00054840213	IPRATROPIUM BR 0.02% SOLN
00054842711	IPECAC SYRUP
00054877505	ROXANOL 5MG SUPPOSITORY
00054877605	ROXANOL 10MG SUPPOSITORY
00054877805	ROXANOL 30MG SUPPOSITORY
00054881025	SODIUM CHLORIDE 0.9% VIAL-NEB.
00597008062	ATROVENT 0.02% SOLUTION
55390003110	METHOTREXATE 25MG/ML VIAL SDV
55390003210	METHOTREXATE 25MG/ML VIAL SDV
55390003410	METHOTREXATE 25MG/ML VIAL SDV
55390018401	BUTORPHANOL 2MG/ML VIAL
55390018402	BUTORPHANOL 2MG/ML VIAL
55390018510	BUTORPHANOL 2MG/ML VIAL
55390029101	ETOPOSIDE 20MG/ML VIAL
55390029201	ETOPOSIDE 20MG/ML VIAL
55390041201	HALOPERIDOL DEC 50MG/ML VL SDV
55390041205	HALOPERIDOL DEC 50MG/ML VL SDV
55390041301	HALOPERIDOL DEC 100MG/ML VL SDV
55390041305	HALOPERIDOL DEC 100MG/ML VL SDV
390046505	FLUPHENAZINE 25MG/ML VIAL